Navigation Links
AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
Date:9/25/2008

VIENNA, Austria, September 25 /PRNewswire/ -- The successful progress of several vaccine programmes run by AFFiRiS GmbH has prompted investor MIG AG to increase its investment in the company. It has set up two new funds - MIG 5 and MIG 7 - to give private investors in Germany and Austria the opportunity to invest in this promising biotech company. The company decided to take this step for two reasons. First, to ensure the early coverage of future capital demand for the continued successful development of vaccines against Alzheimer's disease and atherosclerosis and, second, the tremendous potential that the proprietary AFFITOME platform technology offers the global pharmaceutical market.

The investment group MIG-Fonds announced today that it has increased its investment in AFFiRiS by a further Euro 3 million. As a result, private investors now have another chance to share in the economic success of the biotech company via the MIG Fonds 5 and 7. This news is particularly relevant for private investors in Germany, who have immediate access to MIG 7. This provides investors with the opportunity to make a highly promising investment before the modified capital gains tax comes into force in Germany. Therefore, after a year's holding period, any later profits made from this investment will be tax free.

AFFiRiS will contribute to the success of these funds through its proprietary AFFITOME technology, which is based on the process of molecular mimicry. This technology enables the development of customized vaccines known as AFFITOPE. Dr. Walter Schmidt, co-founder and company CEO, explains the key to the company's AFFiRiS vaccine strategy: "Our patented AFFITOME technology enables scientists to create both molecules with very specific binding characteristics and molecules that differ in structure but exhibit identical binding characteristics. We are currently using these strengths in the development of vaccines against Alzheimer's disease. In the future, AFFITOME technology will also be able to exert a positive influence on other human rogue proteins - such as lipid metabolism enzymes. In line with our strategy of developing medicines for diseases with urgent medical need and attractive market potential, one of our next product candidates can deliver effective results in the treatment of atherosclerosis."

Michael Motschmann, Senior Fund Manager at MIG Fonds, comments on business developments at AFFiRiS GmbH: "In an amazingly short period of time, the company has developed two vaccines against Alzheimer's disease from the initial idea to the first phase I clinical trial, thus underlining the effectiveness of its highly promising business model. We have every reason to believe that these vaccines make interesting product candidates and expect comparable developments to follow in other indications. This progress alone prompted us to make another substantial investment. What's more, the AFFITOME technology behind the development of these vaccines represents an almost inestimable value, which can make the company a very attractive licenser for major pharmaceutical companies."

About AFFiRiS GmbH (as at September 2008):

AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other diseases that urgently require a medical solution. The company has established platform technologies and registered the corresponding patent families. The first patents have already been issued. It employs 35 highly qualified members of staff on 600msquared of rented laboratory facilities at the Campus Vienna Biocenter (http://www.affiris.com).

About MIG-Fonds:

The participation of MIG Verwaltungs AG in Affiris GmbH represents the continuation of a tried-and-tested approach. Investment is only made in selected companies in Germany and Austria after their viability has been thoroughly audited. Its innovative, high-potential products and the entrepreneurial skills of its management teams are both key. MIG Verwaltungs AG is supported by Alfred Wieder AG. This specialist in venture capital is experienced in the sale of holdings and is therefore the first point of contact for any potential investors.

Contact for AFFiRiS GmbH:

Dr. Walter Schmidt

Campus Vienna Biocenter 2

1030 Vienna, Austria

T +43-1-798-15-75-10

E office@affiris.com

Copy Editing & Distribution:

PR&D - Public Relations for Research & Education

Campus Vienna Biocenter 2

1030 Vienna, Austria

T +43-1-505-70-44

E contact@prd.at

W http://www.prd.at


'/>"/>
SOURCE AFFiRiS GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Gerresheimer Further Increases its Sales and Earnings Power
2. OncoGenex increases economic interest in lead cancer drug OGX-011
3. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
4. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
5. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
6. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
7. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
8. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
9. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
10. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
11. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):